DDInter1254 DDInter336
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Nabumetone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Nabumetone {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) PDPK1
PDPK1 {u} (Gene) is bound by {v} (Compound) Celecoxib
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) resembles {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Nabumetone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Celecoxib (Compound)
Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Nabumetone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Nabumetone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoricoxib (Compound) and PTGS2 (Gene) is upregulated by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Nabumetone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Nabumetone (Compound) resembles Naproxen (Compound) and Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Celecoxib (Compound)
Nabumetone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by PDPK1 (Gene) and PDPK1 (Gene) is bound by Celecoxib (Compound)
Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) resembles ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is palliated by Celecoxib (Compound)